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RESEARCH
Risk of stroke and transient ischaemic attack in patients with 
a diagnosis of resolved atrial fibrillation: retrospective cohort 
studies
Nicola J Adderley, Krishnarajah Nirantharakumar, Tom Marshall
ABSTRACT
OBJECTIVES
To determine rates of stroke or transient ischaemic 
attack (TIA) and all cause mortality in patients with a 
diagnosis of “resolved” atrial fibrillation compared to 
patients with unresolved atrial fibrillation and without 
atrial fibrillation.
DESIGN
Two retrospective cohort studies.
SETTING
General practices contributing to The Health 
Improvement Network, 1 January 2000 to 15 May 
2016.
PARTICIPANTS
Adults aged 18 years or more with no previous stroke 
or TIA: 11 159 with resolved atrial fibrillation, 15 059 
controls with atrial fibrillation, and 22 266 controls 
without atrial fibrillation.
MAIN OUTCOME MEASURES
Primary outcome was incidence of stroke or TIA. 
Secondary outcome was all cause mortality.
RESULTS
Adjusted incidence rate ratios for stroke or TIA in 
patients with resolved atrial fibrillation were 0.76 
(95% confidence interval 0.67 to 0.85, P<0.001) 
versus controls with atrial fibrillation and 1.63 (1.46 
to 1.83, P<0.001) versus controls without atrial 
fibrillation. Adjusted incidence rate ratios for mortality 
in patients with resolved atrial fibrillation were 0.60 
(0.56 to 0.65, P<0.001) versus controls with atrial 
fibrillation and 1.13 (1.06 to 1.21, P<0.001) versus 
controls without atrial fibrillation. When patients 
with resolved atrial fibrillation and documented 
recurrent atrial fibrillation were excluded the adjusted 
incidence rate ratio for stroke or TIA was 1.45 
(1.26 to 1.67, P<0.001) versus controls without atrial 
fibrillation.
CONCLUSION
Patients with resolved atrial fibrillation remain at 
higher risk of stroke or TIA than patients without atrial 
fibrillation. The risk is increased even in those in 
whom recurrent atrial fibrillation is not documented. 
Guidelines should be updated to advocate continued 
use of anticoagulants in patients with resolved atrial 
fibrillation.
Introduction
Atrial fibrillation is the most common sustained cardiac 
arrhythmia and is associated with a fivefold increase 
in risk of stroke.1-3 Treatment with anticoagulants 
reduces the risk by about two thirds.4-6
Non-valvular atrial fibrillation is categorised into 
three subtypes: paroxysmal if normal rhythm is 
restored spontaneously; persistent if the episode lasts 
more than seven days or is terminated earlier using 
drug or direct current cardioversion; and permanent 
if cardioversion fails to restore normal heart rhythm.7 8 
Catheter or surgical ablation may be used when 
cardioversion fails or there is evidence of an underlying 
electrophysiological disorder.9 10
Atrial fibrillation can be characterised as resolved 
once normal rhythm is restored, but subsequent 
recurrence is possible after spontaneous resolution 
or cardioversion. Similarly, long term success rates 
of ablation might be as low as 20%.11-13 Patients in 
whom atrial fibrillation is considered resolved might 
in fact have paroxysmal or persistent subtypes, or 
atrial fibrillation that might recur. Such patients might 
remain at an increased risk of stroke and continue to 
benefit from anticoagulant prophylaxis.11
In the United Kingdom no clear guidance exists on 
how to treat patients with resolved atrial fibrillation. 
In clinical guidelines commissioned by the National 
Institute for Health and Care Excellence, patients with 
resolved atrial fibrillation are not explicitly mentioned, 
although for patients who have undergone ablation, 
the guidelines briefly state that the authors “believe 
that common clinical practice is to continue to treat 
patients in accordance with their pre-ablation stroke 
risk score.”2 In England, however, patients with a 
record of resolved atrial fibrillation are excluded from 
the Quality and Outcomes Framework atrial fibrillation 
register, a scheme that incentivises appropriate 
management of patients with atrial fibrillation in 
primary care; guidance issued by NHS England states 
that patients with resolved atrial fibrillation should be 
“removed from the register”14—the implication being 
that these patients do not require further monitoring or 
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WhAT IS AlReAdy knoWn on ThIS TopIC
Atrial fibrillation can recur after apparent resolution, and patients with 
“resolved” atrial fibrillation might therefore continue to be at increased risk of 
stroke or transient ischaemic attack (TIA)
The ongoing risk of stroke in patients with resolved atrial fibrillation is not 
known, however, and there is no clear clinical guidance on how such patients 
should be treated
WhAT ThIS STudy AddS
In UK general practice in 2016, 10.5% of patients with atrial fibrillation 
subsequently had a record showing atrial fibrillation resolved
In 2013-16, patients with a diagnosis of atrial fibrillation resolved were at similar 
risk of stroke or TIA to patients with ongoing atrial fibrillation
Patients with resolved atrial fibrillation are one fifth as likely to receive 
anticoagulants as those with ongoing atrial fibrillation
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anticoagulant treatment. European, Canadian, and US 
guidelines make no reference to patients with resolved 
atrial fibrillation; however, while noting a lack of 
evidence, they do recommend that anticoagulant 
treatment be continued after cardioversion or after 
ablation in patients at high risk of stroke.15-18
To date, there is a dearth of evidence pertaining to 
the prognosis of patients in whom atrial fibrillation 
is coded as resolved. We compared the rates of 
stroke or transient ischaemic attack (TIA) in patients 
with a previous diagnosis of atrial fibrillation who 
were subsequently coded as “atrial fibrillation 
resolved” versus rates in patients with unresolved 
atrial fibrillation and those with no history of atrial 
fibrillation. We also compared all cause mortality in 
patients with resolved atrial fibrillation versus those 
with and without atrial fibrillation. To provide some 
context, we also report the frequency of records 
indicating resolved atrial fibrillation in patients 
with atrial fibrillation from 2000 to the present, and 
anticoagulant treatment rates in patients with atrial 
fibrillation and resolved atrial fibrillation.
Methods
Data source
We extracted datasets from The Health Improvement 
Network (THIN), a database of electronic primary 
care records from UK general practices using Vision 
software. It includes data for approximately 14 million 
patients registered with more than 640 practices. 
THIN comprises coded data on patient characteristics, 
diagnoses, prescriptions, consultations, and 
investigations. We considered practices to be eligible 
for participation from the later of the practice 
acceptable mortality recording date,19 date of Vision 
installation plus one year, and the study start date (one 
year before the first index or census date).
Study design
Prevalence of resolved atrial fibrillation
To determine the proportion of patients with a code 
for “atrial fibrillation resolved” in each study year, we 
performed 17 sequential cross sectional analyses, with 
census dates on 1 December each year from 2000 to 
2016. Adults aged 18 years or more and registered for 
at least 365 days before the census date were eligible 
for inclusion.
Incidence of stroke or TIA and mortality
We carried out two retrospective cohort studies to 
determine incidence rates of stroke or TIA (primary 
outcome) and all cause mortality (secondary outcome) 
in patients with a code for resolved atrial fibrillation 
versus randomly selected matched controls with 
diagnosed (unresolved) atrial fibrillation or no history 
of atrial fibrillation. The study period was 1 January 
2000 to 15 May 2016.
Adults aged 18 years or more and registered for 
at least 365 days before study entry were eligible 
for inclusion. We excluded patients with a history of 
stroke or TIA on the index date. Previous stroke or TIA 
increases the risk of further such events; excluding 
affected patients removes this additional risk and 
minimises surveillance bias. For the matched controls 
without atrial fibrillation, we excluded those with any 
record of an atrial fibrillation diagnosis.
The exposure was a clinical code of “atrial 
fibrillation resolved.” The index date was the coding 
date for resolved atrial fibrillation plus 180 days (six 
months), to allow sufficient time for withdrawal of 
anticoagulant drugs and therefore any residual effect 
of treatment. In sensitivity analysis we used the coding 
date for resolved atrial fibrillation as the index date. We 
matched each exposed patient with up to two controls 
of the same age (to within one year), sex, and general 
practice on the index date, with either diagnosed atrial 
fibrillation and no resolved atrial fibrillation code, or 
with no record of an atrial fibrillation diagnosis.
To randomly select matched controls, we identified 
patients in the exposure group (resolved atrial 
fibrillation) and shuffled their order by randomly 
permuting the patient list (following the Fisher Yates 
algorithm) and using a linear congruential generator 
as the source of randomness. All permutations occur 
with equal likelihood. We then selected the controls. 
Shuffling ensures that all patients in the exposure 
group have an equal chance of being matched to 
a control in instances where that control could 
potentially be matched with more than one exposed 
patient. When the number of possible controls for 
a particular exposed patient exceeded the number 
required (here 2), we used a linear congruential 
generator to generate a random number between 1 
and the number of potential controls; we then selected 
the potential control at the position of this random 
number and repeated the process for the second 
control.
Eligible patients were followed-up from the index 
date until the earliest of any censoring event (patient 
left dataset or transferred out, death, study end date, 
most recent data upload from practice) or an outcome 
event (primary outcome: stroke or TIA; secondary 
outcome: death).
Analysis
All analyses were performed in Stata IC version 14.2.
Frequency of resolved atrial fibrillation
On each census date we calculated the proportion of 
patients with atrial fibrillation who had any record of 
an atrial fibrillation resolved code ever and who had 
a current diagnosis of resolved atrial fibrillation, with 
95% confidence intervals for proportions. On each 
census date we calculated anticoagulant treatment 
rates in patients with atrial fibrillation and resolved 
atrial fibrillation with a moderate to high stroke risk 
(CHA2DS2-VASc score ≥1). Current diagnosis was 
defined using the most recent clinical code before 
census date; current anticoagulant treatment was 
defined as a prescription of any anticoagulant up to 90 
days before census date. We used a χ2 test to calculate 
P values for trends over time.
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Incidence of stroke or TIA and mortality
We assessed baseline differences between the exposure 
and control groups using χ2 tests for categorical 
variables and t tests for continuous variables. Crude 
incidence rates of stroke or TIA (primary outcome) 
and crude all cause mortality (secondary outcome) 
were calculated in patients with resolved atrial 
fibrillation, atrial fibrillation, and no atrial fibrillation. 
We calculated crude and adjusted incidence rate ratios 
comparing the incidence of stroke or TIA and mortality 
in patients with resolved atrial fibrillation versus those 
with and without atrial fibrillation.
Poisson regression was used to calculate adjusted 
incidence rate ratios, adjusting for the baseline 
covariates age, sex, Townsend deprivation fifth, body 
mass index (BMI), smoking status (current smoker), 
alcohol consumption (non-drinker, drinker, excessive 
drinker), Charlson comorbidity index category, 
current statin prescription, and current anticoagulant 
prescription. A sensitivity analysis was carried out in 
which we replaced the Charlson comorbidity index 
covariate with individual comorbidities associated 
with atrial fibrillation: history of heart failure, 
ischaemic heart disease, diabetes (type 1 or type 2), 
and hypertension (binary variables), and estimated 
glomerular filtration rate (eGFR) category. In further 
sensitivity analysis, the regression model included 
any statin or anticoagulant use ever. We checked the 
proportional hazards assumption using log-log plots 
and the Schoenfeld residuals test.
In primary analysis, the index date was the date of 
resolved atrial fibrillation plus 180 days. In a sensitivity 
analysis, we used the atrial fibrillation resolved date as 
index date.
The Nelson-Aalen cumulative hazard function was 
used to plot cumulative hazard of stroke or TIA and 
mortality.
We calculated the proportion (with 95% confidence 
intervals) of patients with resolved atrial fibrillation 
and diagnosed recurrent atrial fibrillation after 
the atrial fibrillation resolved date together with 
the incidence rate of recurrent atrial fibrillation in 
these patients. A subgroup analysis was performed 
comparing the incidence of stroke or TIA in patients 
with resolved atrial fibrillation with and without a 
record of recurrent atrial fibrillation versus patients 
with no atrial fibrillation.
We performed three further subgroup analyses: we 
calculated adjusted incidence rate ratios of stroke or TIA 
in patients with resolved atrial fibrillation whose most 
recent code before atrial fibrillation resolved was for 
paroxysmal atrial fibrillation versus those whose most 
recent code was for other types of atrial fibrillation; 
patients with resolved atrial fibrillation and a recent 
record of ablation (<180 days before the resolved 
code) compared with those without a recent record of 
ablation; and patients with resolved atrial fibrillation 
with a current record of an anticoagulant prescription 
compared with those without a current record.
We calculated the proportion (with 95% confidence 
intervals) of patients with resolved atrial fibrillation 
using current anticoagulant treatment (<90 days before 
atrial fibrillation resolved date) at the time the resolved 
code was recorded, together with the proportions 
using treatment 1-90 days and 91-180 days after the 
atrial fibrillation resolved date. We also calculated the 
proportion of patients with resolved atrial fibrillation 
using current anticoagulants who continued treatment 
up to 90 and 180 days after the atrial fibrillation 
resolved date.
A temporal analysis was carried out by dividing the 
matched datasets into four groups of equal size by 
index date (start dates in 2000, 2007, 2010, and 2013). 
We calculated the crude incidence of stroke or TIA in 
patients with resolved atrial fibrillation, with atrial 
fibrillation, and with no atrial fibrillation, together 
with adjusted incidence rate ratios for resolved atrial 
fibrillation compared to patients with and without 
atrial fibrillation.
Definitions of variables
The presence of a clinical code was used to define atrial 
fibrillation, paroxysmal atrial fibrillation, resolved 
atrial fibrillation, and stroke or TIA; the absence of a 
code was taken to indicate no diagnosis or no outcome 
event. The clinical code lists used have been utilised 
by several atrial fibrillation studies20-22 and include all 
codes used in the Quality and Outcomes Framework.23 
The definition of stroke or TIA included ischaemic 
stroke, haemorrhagic stroke (including intracerebral 
haemorrhage and subarachnoid haemorrhage), and 
transient cerebral ischaemia, transient ischaemic 
attack, or vertebrobasilar insufficiency.
We used the most recent data on BMI and smoking 
status before index date. Alcohol consumption was 
categorised as non-drinker, drinker, and excessive 
drinker; we identified drinkers from data in the THIN 
demography file (most recent record before index date); 
excessive drinker was defined by a record of a clinical 
code (ever). Most recent creatinine level before index 
date was used to calculate eGFR using the formula: 
eGFR=186×(creatinine/88.4)-1.154×age-0.203×(0.742 
if female); the additional correction factor for black 
ethnicity (×1.210 if black) was not included owing 
to incomplete recording of ethnicity. Heart failure, 
ischaemic heart disease, diabetes (type 1 or type 2), 
and hypertension were defined by a record of a relevant 
clinical code (ever); we did not use drugs, physiological 
measures, or laboratory tests to define the presence of 
these diseases.
Recent ablation was defined as a record of a 
procedure code for ablation of the heart up to 180 days 
before the atrial fibrillation resolved date.
We calculated the Charlson comorbidity index 
score by adding 1 point each for peripheral vascular 
disease, ulcer, chronic obstructive pulmonary disease 
or respiratory disease, connective tissue disease, 
dementia, heart failure or coronary heart disease, 
diabetes, mild liver disease, and myocardial infarction; 
2 points each for cancer of the digestive, respiratory, 
or genitourinary tract, leukaemia, lymphoma, cancer 
of the lip, bone, or skin cancer, hemiplegia, and 
RESEARCH
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renal disease or chronic kidney disease; 3 points for 
moderate to severe liver disease; and 6 points each 
for metastatic cancer and HIV/AIDS, each defined by 
a clinical code recorded ever before index date. As 
patients with a history of stroke or TIA were excluded 1 
point was not added for these events.
CHA2DS2-VASc scores were calculated by adding 
1 point each for a history of congestive heart failure, 
hypertension, diabetes, vascular disease, age 65-
74 years, and female sex (if another risk factor was 
present, otherwise 0), and 2 points for age ≥75. As 
we excluded patients with a history of stroke or TIA, 2 
points were not added for these events.
Current statin or anticoagulant use was defined as a 
record of a relevant prescription within 90 days before 
the index date; any use was defined as a record of a 
prescription ever before the index date. Anticoagulants 
included warfarin, parenteral anticoagulants, other 
vitamin K antagonists, and novel oral anticoagulants.
The absence of a diagnostic or prescription code 
was taken to indicate the absence of a disease or drug, 
respectively.
Missing data
Variables were complete except for Townsend score, 
smoking status, drinking status, BMI, and eGFR. 
The absence of a smoking status record was taken to 
indicate the patient was not a current smoker. This is 
consistent with the findings of previous research on 
records of smoking status in primary care records.24 
For Townsend score, drinking status, BMI, and eGFR, 
we used missing indicator categories in the adjusted 
analyses; this assumed missingness was not associated 
with the outcome. We carried out a sensitivity analysis 
using multiple imputation (10 imputations, chained 
equations) to replace missing data; this made no 
difference to the results.
Patient involvement
No patients were involved in setting the research 
question or the outcome measures, nor were 
they involved in developing plans for design or 
implementation of the study. No patients were asked 
to advise on interpretation or writing up of results. 
There are no plans to disseminate the results of the 
research to study participants or the relevant patient 
community.
Results
Prevalence and treatment of resolved atrial 
fibrillation
A total of 1 105 383 records for 222 269 unique 
patients with atrial fibrillation were included in the 
analysis across the 17 census dates, with a median of 
70 096 (interquartile range 52 857-82 242) patients 
each year. The median number of patients with atrial 
fibrillation whose most recent diagnostic code at 
census date was “atrial fibrillation resolved” was 
4627 (interquartile range 970-6534) per year. Across 
all years, the mean age of patients with resolved atrial 
fibrillation was 67.8 (SD 14.8), 60.2% (42 336/70 340) 
were men, and the mean CHA2DS2-VASc score was 2.5 
(SD 1.9); in patients with unresolved atrial fibrillation 
at census date, the corresponding values were 75.3 
(11.4), 54.7% (566 513/1 035 043), and 3.7 (1.7).
Among patients with atrial fibrillation, the 
proportion with any recorded atrial fibrillation 
resolved clinical code ever was 7.8% (95% confidence 
interval 7.8% to 7.9%; 86 615/1 105 383), increasing 
from 0.9% (0.8% to 1.0%; 197/22 008) in 2000 to 
10.5% (10.3% to 10.8%; 6540/62 040) in 2016 
(P<0.001 for trend over time, fig 1). The proportion 
of patients with atrial fibrillation whose most 
recent diagnosis was resolved atrial fibrillation 
increased from 0.8% (0.7% to 0.9%; 178/22 008) 
in 2000 to 7.5% (7.3% to 7.7%; 4627/62 040) 
in 2016 (fig 1). Overall, 78.7% (78.4% to 79.0%; 
55 357/70 340) of these patients were categorised 
as having a moderate to high stroke risk (CHA2DS2-
VASc score ≥1), increasing from 54.5% (46.9% to 
62.0%; 97/178) in 2000 to 84.1% (83.0% to 85.2%; 
3892/4627) in 2016 (P<0.001). Among patients 
with resolved atrial fibrillation and a CHA2DS2-
VASc score of ≥1 on the census date, the proportion 
receiving current anticoagulant treatment increased 
from 6.2% (2.3% to 13.0%; 6/97) in 2000 to 14.3% 
(13.2% to 15.5%; 557/3892) in 2016 (P<0.001 for 
change over time); in patients with unresolved atrial 
fibrillation the treatment rates were 34.3% (33.7% to 
35.0%; 7026/20 479) and 71.8% (71.5% to 72.2%; 
39 746/55 335), respectively (P<0.001).
Incidence of stroke or TIA and mortality
Resolved atrial fibrillation versus atrial fibrillation
A total of 26 218 patients were included in the analysis, 
11 159 patients with resolved atrial fibrillation and 
15 059 controls with atrial fibrillation. Demographic 
and lifestyle characteristics were broadly similar 
between the two groups, with the exception of age: 
on average, patients with resolved atrial fibrillation 
were younger, with a median age of 69.7 (interquartile 
range 58.5-79.0) years compared with 74.2 (66.2-
81.0) years (table 1); this difference is due to the lower 
availability of matched, unexposed patients with atrial 
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Fig 1 | Proportion of patients with atrial fibrillation with a 
record of atrial fibrillation resolved from 2000 to 2016
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fibrillation at younger ages. Patients with resolved 
atrial fibrillation had fewer comorbidities, fewer 
current prescriptions for statins, and substantially 
fewer current prescriptions for anticoagulants.
The crude stroke or TIA incidence rate was 12.1 and 
16.7 per 1000 person years in patients with resolved 
and unresolved atrial fibrillation, respectively; the 
median follow-up period was 2.9 (interquartile range 
1.4-5.7) years (3.5 (1.7–6.5) years in patients with 
resolved atrial fibrillation and 2.7 (1.2-5.1) years in 
patients with atrial fibrillation; the slightly shorter 
follow-up in the latter patients might be explained by 
the higher mortality and other censoring event rates (eg, 
stroke or TIA) in these patients). The crude incidence 
rate ratio was 0.73 (95% confidence interval 0.65 to 
0.81, P<0.001). Adjusting for potential confounders 
(age, sex, Townsend deprivation fifth, BMI, smoking 
status, alcohol consumption, Charlson comorbidity 
index category, current statin prescription, current 
anticoagulant prescription) made little difference to 
the incidence rate ratio: 0.76 (95% confidence interval 
0.67 to 0.85, P<0.001). Figure 2 shows the cumulative 
hazard. In sensitivity analysis, covariates in the 
adjusted model were slightly modified; this made little 
difference to the results (table 2).
The crude mortality rate was 30.0 per 1000 person 
years in patients with resolved atrial fibrillation and 
60.3 per 1000 person years in patients with unresolved 
atrial fibrillation; the median follow-up was 3.1 (1.5-
5.9) years (3.7 (1.8-6.6) in patients with resolved 
atrial fibrillation and 2.8 (1.3-5.4) years in patients 
with atrial fibrillation). Crude and adjusted incidence 
rate ratios were 0.50 (95% confidence interval 0.47 
to 0.53, P<0.001) and 0.60 (0.56 to 0.65, P<0.001), 
respectively (table 2, fig 2).
In additional sensitivity analysis, the date of resolved 
atrial fibrillation was used as index date (rather than 
resolved atrial fibrillation date plus 180 days); this 
made little difference to the incidence rate ratios: 
stroke or TIA crude estimate 0.75 (95% confidence 
interval 0.68 to 0.83, P<0.001), adjusted estimate 0.80 
(0.72 to 0.89, P<0.001); mortality crude estimate 0.50 
Table 1 | Baseline characteristics of patients. Values are numbers (percentages) unless stated otherwise
Characteristics Resolved AF (exposed) (n=11 159) AF (control) (n=15 059) No AF (control) (n=22 266)
Median (interquartile range) age (years) 69.7 (58.5-79.0) 74.2 (66.2-81.0) 69.6 (58.5-78.9)
Men 6561 (58.8) 8734 (58.0) 13 096 (58.8)
Townsend deprivation fifth:
 1st (least deprived) 3210 (28.8) 4291 (28.5) 6367 (28.6)
 2nd 2732 (24.5) 3565 (23.7) 5247 (23.6)
 3rd 2248 (20.2) 2969 (19.7) 4347 (19.5)
 4th 1642 (14.7) 2396 (15.9) 3498 (15.7)
 5th (most deprived) 1023 (9.2) 1466 (9.7) 2217 (10.0)
 Missing 304 (2.7) 372 (2.5) 590 (2.7)
Current smoker* 1070 (9.6) 1279 (8.5) 3244 (14.6)
Drinking status:
 Non-drinker 2160 (19.4) 3287 (21.8) 4177 (18.8)
 Drinker 7541 (67.6) 10123 (67.2) 14711 (66.1)
 Excessive drinker 511 (4.6) 597 (4.0) 609 (2.7)
 Missing 947 (8.5) 1052 (7.0) 2769 (12.4)
BMI (kg/m2):
 <25 3459 (31.0) 4316 (28.7) 7498 (33.7)
 25-30 3855 (34.6) 5294 (35.2) 7572 (34.0)
 >30 2874 (25.8) 4414 (29.3) 4349 (19.5)
 Missing 971 (8.7) 1035 (6.9) 2847 (12.8)
Charlson comorbidity index:
 0 5052 (45.3) 5173 (34.4) 12446 (55.9)
 1 2606 (23.4) 3757 (25.0) 4782 (21.5)
 2 1767 (15.8) 2887 (19.2) 2860 (12.8)
 3 909 (8.2) 1655 (11.0) 1196 (5.4)
 ≥4 825 (7.4) 1587 (10.5) 982 (4.4)
Hypertension 5392 (48.3) 8535 (56.7) 8155 (36.6)
Diabetes 1374 (12.3) 2740 (18.2) 2315 (10.4)
Heart failure 1016 (9.1) 2877 (19.1) 437 (2.0)
Ischaemic heart disease 2199 (19.7) 4346 (28.9) 2559 (11.5)
eGFR category (ml/min/1.73m2):
 >90 1831 (16.4) 1902 (12.6) 3077 (13.8)
 60-90 5707 (51.1) 7874 (52.3) 10 323 (46.4)
 30-59 2315 (20.8) 4245 (28.2) 3323 (14.9)
 <30 175 (1.6) 341 (2.3) 205 (0.9)
 Missing 1131 (10.1) 697 (4.6) 5338 (24.0)
Current statin prescription 3933 (35.3) 7066 (46.9) 5896 (26.5)
Current anticoagulant prescription 926 (8.3) 8090 (53.7) 248 (1.1)
AF=atrial fibrillation; BMI=body mass index; eGFR=estimated glomerular filtration rate.
*Absence of a record of current smoker was taken to indicate patient was not a current smoker. 99.0% of patients with atrial fibrillation resolved, 99.3% with atrial fibrillation and 96.5% 
without atrial fibrillation had a recorded smoking code.
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(0.47 to 0.53, P<0.001), adjusted estimate 0.61 (0.58 
to 0.65, P<0.001) (see supplementary table 1).
Resolved atrial fibrillation versus no atrial fibrillation
A total of 33 425 patients were included in the analysis: 
11 159 patients with resolved atrial fibrillation and 
22 266 controls with no record of atrial fibrillation. 
Demographic and lifestyle characteristics were similar 
between the two groups, although smokers were fewer 
among patients with resolved atrial fibrillation: 9.6% 
(1070/11 159) compared with 14.6% (3244/22 266) 
in the control group. Patients with resolved atrial 
fibrillation had more comorbidities, and more had a 
current prescription for a statin or anticoagulant.
The crude stroke or TIA incidence rate was 12.1 and 
7.4 per 1000 person years in patients with resolved 
atrial fibrillation and no atrial fibrillation, respectively; 
median follow-up was 3.5 (interquartile range 1.7-
6.5) years (median and interquartile range were the 
same in both patient groups). The crude incidence 
rate ratio was 1.65 (95% confidence interval 1.47 to 
1.84, P<0.001) and the adjusted incidence rate ratio 
was 1.63 (1.46 to 1.83, P<0.001). Figure 2 shows 
the cumulative hazard. Modifying the covariates in 
the adjusted model in sensitivity analysis made little 
difference to the results (table 2).
The crude mortality rate was 30.0 per 1000 person 
years in patients with resolved atrial fibrillation 
and 24.4 per 1000 person years in patients with 
no atrial fibrillation; the median follow-up was 3.6 
(interquartile range 1.7-6.6) years (3.7 (1.8-6.6) years 
in patients with resolved atrial fibrillation and 3.6 (1.7-
6.6) years in patients with no atrial fibrillation). The 
crude and adjusted incidence rate ratios were 1.23 
(95% confidence interval 1.15 to 1.31, P<0.001) and 
1.13 (1.06 to 1.21, P<0.001), respectively (table 2, 
fig 2).
Using the date for resolved atrial fibrillation as index 
date in sensitivity analysis made little difference to 
the mortality incidence rate ratio, but the incidence 
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Fig 2 | Unadjusted Nelson-Aalen cumulative hazard estimates for stroke or transient ischaemic attack (TIA) in 
patients with resolved atrial fibrillation versus unresolved atrial fibrillation; mortality in patients with resolved atrial 
fibrillation versus unresolved atrial fibrillation; stroke or TIA in patients with resolved atrial fibrillation versus no 
atrial fibrillation; mortality in patients with resolved atrial fibrillation versus no atrial fibrillation (see supplementary 
figure 1 for adjusted cumulative hazard estimates)
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rate ratio for stroke or TIA increased: crude incidence 
rate ratio 1.82 (95% confidence interval 1.64 to 2.02, 
P<0.001) and adjusted incidence rate ratio 1.82 
(1.62 to 2.03, P<0.001); mortality crude incidence 
rate ratio 1.22 (1.15 to 1.30, P<0.001) and adjusted 
incidence rate ratio 1.14 (1.07 to 1.22, P<0.001) (see 
supplementary table 1).
Subgroup analysis
Overall, 22.8% (2539/11 159) of patients with 
resolved atrial fibrillation had a subsequent record of 
recurrent atrial fibrillation. The incidence of recurrent 
atrial fibrillation was 63.6 per 1000 person years.
The incidence of stroke or TIA in patients with 
resolved atrial fibrillation with a record of recurrent 
atrial fibrillation was 16.0 per 1000 person years 
compared with 10.5 per 1000 person years in 
patients with no record of recurrent atrial fibrillation. 
Compared with patients without atrial fibrillation, 
the crude and adjusted incidence rate ratios for 
stroke or TIA were 2.04 (95% confidence interval 
1.69 to 2.47, P<0.001) and 2.05 (1.69 to 2.50, 
P<0.001), respectively, for patients with resolved 
atrial fibrillation and a record of recurrent atrial 
fibrillation, and 1.46 (1.27 to 1.68, P<0.001) and 1.45 
(1.26 to 1.67, P<0.001), respectively, for patients with 
resolved atrial fibrillation and no record of recurrent 
atrial fibrillation (table 3).
Among patients coded as having atrial fibrillation 
resolved, 18.8% (2095/11 159) had received a 
diagnosis of paroxysmal atrial fibrillation before atrial 
fibrillation resolved (most recent atrial fibrillation 
diagnostic code before atrial fibrillation resolved). 
Incidence of stroke or TIA after coded atrial fibrillation 
resolved was not statistically significantly different 
between patients previously coded as having 
paroxysmal atrial fibrillation and those coded as having 
other types of atrial fibrillation before the resolved 
atrial fibrillation diagnosis: adjusted incidence rate 
ratio 1.17 (95% confidence interval 0.95 to 1.45). The 
reference group comprised all patients with resolved 
atrial fibrillation without a previous paroxysmal atrial 
fibrillation code.
A recent record of ablation was documented in 
1.2% (131/11 159) of patients with resolved atrial 
fibrillation. Incidence of stroke or TIA after coded 
atrial fibrillation resolved was not statistically 
significantly different in patients with a recent record 
of ablation compared with those without: adjusted 
incidence rate ratio 0.68 (95% confidence interval 
0.22 to 2.14). The number of outcome events in those 
who had a record of ablation was, however, small 
(n=3). The reference group comprised all patients 
with coded atrial fibrillation resolved with no recent 
record of ablation.
Anticoagulant treatment
In total, 17.4% (95% confidence interval 16.7% to 
18.1%; 1943/11 159) of patients with coded atrial 
fibrillation resolved had a current prescription for 
anticoagulant at the time the diagnosis of resolved 
atrial fibrillation was recorded. Overall, 9.6% (9.1% to 
10.2%; 1071/11 159) were prescribed anticoagulants 
up to 90 days after the atrial fibrillation resolved 
date, and 8.2% (7.7% to 8.8%; 950/11 159) had a 
prescription 91 to 180 days after the atrial fibrillation 
resolved date. Of the 1943 (17.4%) patients with a 
current prescription for anticoagulant at the time the 
diagnosis of resolved atrial fibrillation was recorded, 
44.9% (42.7% to 47.1%; 872/1943) were still 
Table 2 | Incidence rate ratios for stroke or transient ischaemic attack and mortality in patients with resolved atrial fibrillation versus patients with 
and without atrial fibrillation. Values are numbers (percentages) unless stated otherwise
Variables
Resolved AF versus AF Resolved AF versus no AF
Exposed (n=11 159) Control (n=15 059) Exposed (n=11 159) Control (n=22 266)
Stroke or TIA (primary outcome)
Outcome events 568 (5.1) 852 (5.7) 568 (5.1) 683 (3.1)
Person years 46 823.02 51 113.68 46 823.02 92 774.54
Crude incidence rate* 12.1 16.7 12.1 7.4
IRR (95% CI), P value:
 Crude 0.73 (0.65 to 0.81), <0.001 1.65 (1.47 to 1.84), <0.001
 Adjusted: model 1 0.76 (0.67 to 0.85), <0.001 1.63 (1.46 to 1.83), <0.001
 Adjusted: model 2 0.76 (0.67 to 0.86), <0.001 1.60 (1.43 to 1.80), <0.001
 Adjusted: model 3 0.83 (0.74 to 0.93), 0.001 1.59 (1.41 to 1.80), <0.001
Mortality (secondary outcome)
Outcome events 1448 (13.0) 3207 (21.3) 1448 (13.0) 2309 (10.4)
Person years 48 214.51 53 203.11 48 214.51 94 561.84
Crude incidence rate* 30.0 60.3 30.0 24.4
IRR (95% CI), P value†:
 Crude 0.50 (0.47 to 0.53), <0.001 1.23 (1.15 to 1.31), <0.001
 Adjusted: model 1 0.60 (0.56 to 0.65), <0.001 1.13 (1.06 to 1.21), <0.001
 Adjusted: model 2 0.62 (0.58 to 0.67), <0.001 1.11 (1.03 to 1.19), 0.004
 Adjusted: model 3 0.64 (0.60 to 0.68), <0.001 1.09 (1.01 to 1.17), 0.019
AF=atrial fibrillation; TIA=transient ischaemic attack; IRR=incidence rate ratio.
*Rate per 1000 person years.
†IRR adjusted for: model 1: age, sex, Townsend deprivation fifth, body mass index (BMI), smoking status, alcohol consumption, Charlson comorbidity index category, current statin prescription, 
current anticoagulant prescription; model 2: age, sex, Townsend deprivation fifth, BMI, smoking status, alcohol consumption, history of heart failure, history of ischaemic heart disease, history 
of diabetes, hypertension, estimated glomerular filtration rate (eGFR) category, current statin prescription, current anticoagulant prescription; model 3: age, sex, Townsend deprivation fifth, BMI, 
smoking status, alcohol consumption, Charlson comorbidity index category, statin prescription ever, anticoagulant prescription ever.
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receiving anticoagulant treatment up to 90 days later, 
and 32.9% (30.8% to 35.0%; 639/1943) were still 
receiving treatment up to 180 days later.
The proportion of patients coded as atrial fibrillation 
resolved with a current record of an anticoagulant 
prescription at the index date (up to 90 days before 
index, equivalent to 90-180 days after the atrial 
fibrillation resolved record) was 8.3% (926/11 159). 
The crude incidence of stroke or TIA in patients with 
resolved atrial fibrillation and a current prescription 
for an anticoagulant was 11.4 per 1000 person years, 
compared with 12.2 per 1000 person years in patients 
without. The adjusted incidence of stroke or TIA was 
14% lower in patients with a current prescription for 
an anticoagulant compared with those without, but 
this result was not statistically significant: adjusted 
incidence rate ratio 0.86 (95% confidence interval 
0.62 to 1.18).
Temporal trends
A temporal analysis was carried out by dividing the 
datasets into four groups of equal size by index date 
(start dates in 2000, 2007, 2010, and 2013). The crude 
incidence of stroke or TIA in patients with resolved 
atrial fibrillation increased over the four temporal 
datasets: 10.2, 12.3, 13.8, and 18.5 per 1000 person 
years in 2000, 2007, 2010, and 2013, respectively. 
In patients with and without atrial fibrillation, 
the incidence of stroke or TIA was more constant: 
incidence rate for patients with atrial fibrillation 17.9, 
15.4, 16.5, and 16.6 per 1000 person years in 2000, 
2007, 2010, and 2013, respectively; incidence rate for 
patients without atrial fibrillation 7.3, 7.2, 6.8, and 
9.4 per 1000 person years in 2000, 2007, 2010, and 
2013, respectively. The adjusted incidence rate ratios 
for patients with resolved atrial fibrillation versus 
those with atrial fibrillation across these four temporal 
groups were 0.67 (95% confidence interval 0.55 to 
0.81), 0.81 (0.65 to 1.00), 0.79 (0.61 to 1.02), and 
0.96 (0.67 to 1.39). Adjusted incidence rate ratios for 
resolved atrial fibrillation versus no atrial fibrillation 
across these four groups were 1.32 (1.09 to 1.60), 1.75 
(1.43 to 2.15), 1.94 (1.50 to 2.50), and 1.98 (1.43 to 
2.74), respectively.
Exclusion of unmatched patients with resolved 
atrial fibrillation
Where available, each patient with resolved atrial 
fibrillation was matched with two controls of the same 
age, sex, and general practice. Matched controls were 
not available for every patient however. This was not a 
major problem in the dataset of patients with resolved 
atrial fibrillation versus those with no atrial fibrillation, 
in which 13 (out of 11 159) patients with resolved 
atrial fibrillation were unmatched. The unavailability 
of a match might be related to the older age of these 13 
patients (91-104 years).
In the dataset of patients with resolved atrial 
fibrillation versus those with atrial fibrillation, however, 
2743 patients with resolved atrial fibrillation were 
unmatched. This arose because of the comparatively 
smaller pool of patients with atrial fibrillation from 
which controls could be selected, particularly in 
smaller practices. The median age of patients without 
a match was 52.4 (interquartile range 43.8-62.1) 
years, whereas the median age of patients with one 
or two matches was 74.0 (65.8-80.8) years, which 
explains the difference in age observed in the baseline 
characteristics. Age was included as a covariate in the 
adjusted analyses.
Table 3 | Incidence rate ratios for stroke or transient ischaemic attack and mortality in patients with resolved atrial fibrillation with and without 
recurrent atrial fibrillation versus matched controls without atrial fibrillation. Values are numbers (percentages) unless stated otherwise
Variables
Resolved AF with recurrent AF versus no AF Resolved AF without recurrent AF versus no AF
Exposed (n=2539) Control (n=5068) Exposed (n=8620) Control (n=17 198)
Stroke or TIA (primary outcome)
Outcome events 225 (8.9) 205 (4.0) 343 (4.0) 478 (2.8)
Person years 14 043.82 26 130.03 32 779.21 66 644.51
Crude incidence rate* 16.0 7.8 10.5 7.2
IRR (95% CI), P value:
 Crude 2.04 (1.69 to 2.47), <0.001 1.46 (1.27 to 1.68), <0.001
 Adjusted: model 1 2.05 (1.69 to 2.50), <0.001 1.45 (1.26 to 1.67), <0.001
 Adjusted: model 2 2.01 (1.64 to 2.45), <0.001 1.42 (1.23 to 1.64), <0.001
 Adjusted: model 3 2.01 (1.62 to 2.50), <0.001 1.43 (1.23 to 1.66), <0.001
Mortality (secondary outcome)
Outcome events 277 (10.9) 591 (11.7) 1171 (13.6) 1718 (10.0)
Person years 14 684.55 26 740.34 33 529.96 67 821.5
Crude incidence rate* 18.8 22.1 34.9 25.3
IRR (95% CI), P value†:
 Crude 0.85 (0.74 to 0.98), 0.03 1.38 (1.28 to 1.48), <0.001
 Adjusted: model 1 0.77 (0.67 to 0.90), 0.001 1.26 (1.17 to 1.36), <0.001
 Adjusted: model 2 0.76 (0.65 to 0.89), <0.001 1.23 (1.14 to 1.33), <0.001
 Adjusted: model 3 0.75 (0.63 to 0.88), 0.001 1.21 (1.11 to 1.31), <0.001
AF=atrial fibrillation; TIA=transient ischaemic attack; IRR=incidence rate ratio.
*Incidence per 1000 person years.
†IRR adjusted for: model 1: age, sex, Townsend deprivation fifth, body mass index (BMI), smoking status, alcohol consumption, Charlson comorbidity index category, current statin prescription, 
current anticoagulant prescription; model 2: age, sex, Townsend deprivation fifth, BMI, smoking status, alcohol consumption, history of heart failure, history of ischaemic heart disease, history 
of diabetes, hypertension, estimated glomerular filtration rate (eGFR) category, current statin prescription, current anticoagulant prescription; model 3: age, sex, Townsend deprivation fifth, BMI, 
smoking status, alcohol consumption, Charlson comorbidity index category, statin prescription ever, anticoagulant prescription ever.
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A sensitivity analysis was carried out excluding 
patients with resolved atrial fibrillation with no 
matched controls. This made no difference to the 
results: in patients with resolved atrial fibrillation 
versus those with atrial fibrillation, the adjusted 
incidence rate ratios for stroke or TIA and death were 
0.80 (95% confidence interval 0.71 to 0.91) and 0.60 
(0.56 to 0.65), respectively; in patients with resolved 
atrial fibrillation versus those with no atrial fibrillation, 
the corresponding values were 1.64 (1.46 to 1.83) and 
1.13 (1.06 to 1.21).
discussion
The clinical code “atrial fibrillation resolved” is 
widely used in general practice, with more than 10% 
of patients with atrial fibrillation in the UK currently 
having any record of the code. Between 2000 and 
2013, use of the code increased considerably; 
prevalence of a record of atrial fibrillation resolved 
increased alongside increased prevalence of recorded 
atrial fibrillation in the UK during the same period.25 26 
A sharp increase occurred in the proportion of patients 
coded as atrial fibrillation resolved in 2006/07. This 
coincides with the introduction of atrial fibrillation 
into the Quality and Outcomes Framework (2006), 
when it will have been in the interests of general 
practices to review the diagnosis in patients on the 
atrial fibrillation register, in particular those who were 
not receiving antithrombotic treatment, for instance 
by recoding such patients as having atrial fibrillation 
resolved where it was considered to be appropriate. 
A slight decline has taken place in recent years, 
but a substantial proportion of patients with atrial 
fibrillation continue to be categorised as having atrial 
fibrillation resolved.
In patients with a diagnosis of resolved atrial 
fibrillation the rates for stroke or TIA are lower than 
in patients with unresolved atrial fibrillation but are 
60% higher than in patients with no history of atrial 
fibrillation. Even when patients with a subsequent 
record of recurrent atrial fibrillation were excluded 
from the analysis, stroke or TIA rates were 45% greater 
in patients with resolved atrial fibrillation than in 
those with no history of atrial fibrillation. Mortality 
rates were approximately 10% higher in patients with 
resolved atrial fibrillation than in those with no atrial 
fibrillation.
Lower incidence rates of stroke or TIA in patients 
with an atrial fibrillation resolved code versus patients 
with atrial fibrillation might reflect the heterogeneous 
nature of this group. Some may no longer have atrial 
fibrillation and have permanently returned to sinus 
rhythm, some may have been misdiagnosed as having 
atrial fibrillation and subsequently found not to have 
atrial fibrillation, and some may have more intermittent 
or episodic atrial fibrillation such as the paroxysmal 
subtype. Some evidence suggests that the risk of stroke 
is lower in patients with paroxysmal atrial fibrillation 
compared with those with persistent or permanent 
atrial fibrillation,27 28 although risk remains increased 
compared with patients without atrial fibrillation. 
Nevertheless, it is evident that as a group, patients 
coded as having resolved atrial fibrillation remain at 
a statistically significantly increased risk of stroke 
or TIA.
Furthermore, stroke or TIA rates in patients with 
resolved atrial fibrillation increased over time. This 
could be linked to the increasing prevalence of this 
code in patient records, perhaps indicating that its 
use has been extended over time to include a greater 
number of patients with silent, intermittent, or 
recurring atrial fibrillation. From 2007, there was no 
statistically significant difference between rates for 
stroke or TIA in patients coded as atrial fibrillation 
resolved and those with atrial fibrillation. From 2010, 
stroke or TIA rates in patients with resolved atrial 
fibrillation were double those in patients with no 
history of atrial fibrillation.
It is therefore likely that patients with resolved atrial 
fibrillation would benefit from continued anticoagulant 
prophylaxis. This analysis, however, shows that only a 
relatively small proportion of such patients continue 
anticoagulant treatment after diagnosis: in 2016, 
treatment rates were 80% lower in patients with a 
diagnosis of resolved atrial fibrillation than in patients 
with unresolved atrial fibrillation.
Comparison with existing literature and 
recommendations
The observed crude incidence rate ratio for stroke or TIA 
in patients with atrial fibrillation versus those without 
atrial fibrillation was 2.3 (95% confidence interval 2.0 
to 2.5) (although it should be noted that both groups 
were matched to the exposure group, atrial fibrillation 
resolved, rather than to each other). This is similar to 
the relative rates observed in other routinely collected 
primary care datasets, in which many patients with 
atrial fibrillation are prescribed anticoagulant drugs in 
accordance with clinical guidelines.29 30
While successful ablation in patients with atrial 
fibrillation might lead to the restoration of normal 
heart rhythm in the short term, evidence from 
studies with long term follow-up suggests that atrial 
fibrillation may recur in up to 80% of patients.11-13 
Several studies have investigated long term outcomes 
in patients who have undergone ablation, with results 
indicating reduced stroke risk in patients with atrial 
fibrillation who have undergone ablation versus those 
who have not undergone ablation,31 and versus those 
who have undergone cardioversion.32 Few, however, 
have compared stroke rates to those in patients with 
no history of atrial fibrillation; one exception is a 
cohort study in the United States, which found that 
stroke rates in patients with atrial fibrillation who 
underwent ablation were similar to those in patients 
with no history of atrial fibrillation, although no data 
were available to indicate whether or not patients 
were prescribed anticoagulants.33 A study using 
international data, which included patients with atrial 
fibrillation and a moderate to high risk of stroke and 
taking warfarin or rivaroxaban, found no difference 
between stroke rates before and after cardioversion 
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or ablation; however, the study population and the 
number of outcome events were small.34
Ablation may be one of several reasons to categorise 
atrial fibrillation as having resolved; in our dataset, only 
1.2% of patients with resolved atrial fibrillation had a 
recent record of ablation. No studies investigating the 
prognosis of patients with resolved atrial fibrillation 
more broadly have been identified.
This lack of evidence might explain the limited 
guidance offered in UK and international guidelines 
concerning the treatment of patients with resolved 
atrial fibrillation, this being restricted to brief notes 
on patients who have undergone ablation; remarks 
that generally conflict with the fact that patients 
coded as “atrial fibrillation resolved” are explicitly 
excluded from atrial fibrillation registers in England.2 
14-16 In light of the evidence produced by this study, it 
is recommended that clinical guidelines and schemes 
designed to incentivise appropriate management of 
patients with atrial fibrillation are updated to promote 
continuation of anticoagulant prophylaxis in patients 
with resolved atrial fibrillation, or, alternatively, to 
deprecate continued use of this specious categorisation.
Strengths and limitations of this study
The analysis utilised a large general practice 
database that is generalisable to the UK population 
and comprises routine clinical data used in decision 
making by general practitioners.
Usage and interpretation of the atrial fibrillation 
resolved clinical code are likely to vary between 
clinicians and practices; the resulting group of 
patients with resolved atrial fibrillation will therefore 
be heterogeneous. However, the code has important 
clinical relevance as it obviates the need to include 
these patients in the register of patients with atrial 
fibrillation, and therefore removes the requirement 
to systematically ensure that they are prescribed 
anticoagulants. Coded recording of medical conditions 
may be incomplete; however, atrial fibrillation and 
stroke, along with comorbidities such as diabetes 
and hypertension, which are part of the Quality and 
Outcomes Framework, are likely to be well recorded 
in periods where this was incentivised. Ethnicity is 
poorly recorded in general practice, although this has 
improved in recent years, and so it was not possible 
to include ethnic group as a covariate. Townsend 
scores are based on postcode and may not accurately 
represent deprivation at an individual level, but 
they should be broadly representative across the 
populations studied.
Some patients receiving anticoagulants might not 
have been identified if the treatment was managed 
entirely in secondary care, leading to the possibility 
of underestimated treatment rates; however, most 
anticoagulants are prescribed in primary care and any 
underestimation is therefore likely to be small. The 
database provides information only on prescriptions 
issued; it is not possible to ascertain whether the 
prescriptions were collected, or the extent of drug 
compliance.
The age gap between patients with resolved atrial 
fibrillation and the matched controls with atrial 
fibrillation was 4.5 years. This was because of the 
relatively small numbers of patients with atrial 
fibrillation from which controls could be selected, 
particularly in small practices. Age was, however, 
adjusted for in the analysis. Furthermore, results were 
robust to sensitivity analyses in which unmatched 
patients were excluded.
In the analysis of stroke or TIA, patients who died 
were censored at the date of death; death is therefore 
a competing risk. This might result in slightly inflated 
crude rates for stroke or TIA. Poisson regression assumes 
a constant baseline hazard; however, results did not 
differ when we carried out a sensitivity analysis using 
Cox regression, which does not make this assumption.
Conclusions
Patients with a diagnosis of resolved atrial fibrillation 
have increased as a proportion of patients with atrial 
fibrillation. They remain at a 60% greater risk of stroke 
or TIA than patients without atrial fibrillation. These 
patients would benefit from continued anticoagulant 
prophylaxis, but treatment rates in this group are 
extremely low. It is recommended that national and 
international guidelines are updated to advocate 
continued use of anticoagulant treatment in patients 
with resolved atrial fibrillation.
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